The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 31, 2005
Filed:
Mar. 19, 2002
Mark Stuart Chambers, Puckeridge, GB;
Simon Charles Goodacre, Benington, GB;
David James Hallett, Watford, GB;
Andrew Jennings, Sawbridgworth, GB;
Philip Jones, Bishops Stortford, GB;
Richard Thomas Lewis, Bishops Stortford, GB;
Kevin William Moore, Buntingford, GB;
Michael Geoffrey Neil Russell, Welwyn Garden City, GB;
Leslie Joseph Street, Little Hallingbury, GB;
Helen Jane Szekeres, Roydon, GB;
Mark Stuart Chambers, Puckeridge, GB;
Simon Charles Goodacre, Benington, GB;
David James Hallett, Watford, GB;
Andrew Jennings, Sawbridgworth, GB;
Philip Jones, Bishops Stortford, GB;
Richard Thomas Lewis, Bishops Stortford, GB;
Kevin William Moore, Buntingford, GB;
Michael Geoffrey Neil Russell, Welwyn Garden City, GB;
Leslie Joseph Street, Little Hallingbury, GB;
Helen Jane Szekeres, Roydon, GB;
Merck Sharp & Dohme Ltd., Hoddesdon, GB;
Abstract
A class of 3-phenylimidazo[1,2-α]pyrimidine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, and further substituted on the phenyl ring by alkyl, trifluoromethyl, alkoxy or one or two halogen atoms, especially fluoro, are selective ligands for GABAreceptors, in particular having good affinity for the α2 and/or α3 and/or α5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.